MYB — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL14478940	0.73	19/20
SCHEMBL4335346	1.00	18/20
SCHEMBL20368759	0.90	18/20
SCHEMBL5044963	0.89	18/20
SCHEMBL4327922	0.83	18/20
SCHEMBL4325696	0.78	18/20
SCHEMBL12136727	0.75	18/20
SCHEMBL20368770	0.72	18/20
SCHEMBL8808882	0.58	18/20
SCHEMBL8539407	0.58	18/20
SCHEMBL8539876	0.56	18/20
SCHEMBL8539879	0.56	18/20
SCHEMBL8543671	1.00	17/20
SCHEMBL15614738	1.00	17/20
SCHEMBL6014204	0.89	17/20
SCHEMBL5048163	0.89	17/20
SCHEMBL4331540	0.87	17/20
SCHEMBL4534455	0.83	17/20
SCHEMBL8538963	0.80	17/20
SCHEMBL5044967	0.59	17/20

Clinical trials — most relevant to MYB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population	PHASE2	ACTIVE_NOT_RECRUITING
Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients	PHASE2	COMPLETED
Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy	PHASE2	COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)	PHASE2	RECRUITING
A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;	PHASE2	COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
MicroRNA-150 and microRNA-155 in Multiple Sclerosis	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Immune Interactions in Severe Asthma	nan	COMPLETED
Mild Intermittent Hypoxia and Its Multipronged Effect on Sleep Apnea	nan	RECRUITING
Timisnar - Biomarkers Substudy (Timisnar-mirna)	nan	UNKNOWN
Effect of Exercise on the Human Skeletal Muscle Phosphoproteome	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.	nan	UNKNOWN
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
The Role of TBX3 in Human ES Cell Differentiation	nan	WITHDRAWN
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis	nan	COMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
DNA Methylation and Autoimmune Thyroid Diseases	nan	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
Role of Vitamin C Infusion in Postoperative Mechanically Ventilated Neonates With Sepsis	nan	COMPLETED
Vascular Endothelial Factor Gene Polymorphism in Preeclampsia	nan	COMPLETED
Molecular Hydrogen Inhalation: Effects on Health, Exercise Capacity and Inflammatory Response - in Vivo/in Vitro Studies	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MYB binder may also engage these)

Protein	Name	Similarity
P46200	—	1.000	P46200 →
P01103	—	1.000	P01103 →
P10244	—	1.000	P10244 →
P06876	—	1.000	P06876 →
P52550	—	0.998	P52550 →
Q05935	—	0.997	Q05935 →
Q90655	—	0.997	Q90655 →
Q03237	—	0.996	Q03237 →
P70284	—	0.996	P70284 →
Q949U2	—	0.995	Q949U2 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.994	landscape →
Q3YC04	—	0.994	Q3YC04 →
Q29131	—	0.994	Q29131 →
Q90ZS6	—	0.994	Q90ZS6 →
P52551	—	0.994	P52551 →
Q8VII8	—	0.994	Q8VII8 →
P48972	—	0.994	P48972 →
O43310	—	0.993	O43310 →
Q4JM28	—	0.993	Q4JM28 →
Q08759	—	0.993	Q08759 →
P06536	—	0.993	P06536 →
Q0P4H6	—	0.993	Q0P4H6 →
P06537	—	0.993	P06537 →
Q5WM45	—	0.993	Q5WM45 →
P22199	—	0.993	P22199 →
BMP2K	BMP-2-inducible protein kinase	0.993	landscape →
A7MBB4	—	0.992	A7MBB4 →
Q0JHU7	—	0.992	Q0JHU7 →
Q8R4I4	—	0.992	Q8R4I4 →
Q6YXZ4	—	0.992	Q6YXZ4 →